Xencor (XNCR) Depreciation & Amortization (CF) (2013 - 2026)
Xencor (XNCR) posted quarterly Depreciation & Amortization (CF) of $2.6 million for Q1 2026, down 4.68% year-over-year from $2.7 million in Q1 2025, and little changed quarter-over-quarter from $2.6 million in Q4 2025.
Analysis
Xencor (XNCR) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Depreciation & Amortization (CF) for 14 consecutive years, with $2.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 4.68% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $10.4 million (down 11.72% YoY), while the FY2025 annual figure was $10.5 million, down 13.17% from the prior year.
- Depreciation & Amortization (CF) steadied at $2.6 million in Q1 2026 per XNCR's latest filing, from $2.6 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $3.2 million in Q4 2023 and bottomed at $2.2 million in Q4 2022.
- Historically, Depreciation & Amortization (CF) has averaged $2.7 million across 5 years, with a median of $2.7 million in 2025.
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) jumped 49.51% — and 2025, when it dropped 15.23%.
- Xencor's Depreciation & Amortization (CF) stood at $2.2 million in 2022, then jumped by 49.51% to $3.2 million in 2023, then dropped by 7.25% to $3.0 million in 2024, then declined by 13.93% to $2.6 million in 2025, then fell by 0.39% to $2.6 million in 2026.
- Business Quant data shows XNCR's Depreciation & Amortization (CF) at $2.6 million in Q1 2026, $2.6 million in Q4 2025, and $2.6 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Xencor | 2.02 Bn | 1.65 Bn | - | 2.44 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.44 Mn |
| Mar 31, 2026 | 2.57 Mn |
| Dec 31, 2025 | 2.58 Mn |
| Sep 30, 2025 | 2.59 Mn |
| Jun 30, 2025 | 2.65 Mn |
| Mar 31, 2025 | 2.69 Mn |
| Dec 31, 2024 | 2.99 Mn |
| Sep 30, 2024 | 3.05 Mn |
| Jun 30, 2024 | 3.02 Mn |
| Mar 31, 2024 | 3.04 Mn |
| Dec 31, 2023 | 3.23 Mn |
| Sep 30, 2023 | 3.14 Mn |
| Jun 30, 2023 | 2.89 Mn |
| Mar 31, 2023 | 2.25 Mn |
| Dec 31, 2022 | 2.16 Mn |
| Sep 30, 2022 | 2.24 Mn |
| Jun 30, 2022 | 2.22 Mn |
| Mar 31, 2022 | 2.18 Mn |
| Dec 31, 2021 | 2.11 Mn |
| Sep 30, 2021 | 1.99 Mn |